Lexsential is proud to have supported 1MED, a Contract Research Organization (CRO) specialising in high-quality regulatory and clinical services for pharmaceutical, medical, and biotechnology companies, along with UK-based private equity fund Apposite Capital, exclusively focused on the healthcare and medical sector, in the integration of LB Research.

Our team included partners Stefano Candela and Pasquale Di Mino, associate Marta Cosi, associates Teresa Candela and Silvia Sarracino, and of counsel Sabrina Peron and Antonio Di Mino.

LB Research, a leading CRO with comprehensive clinical trial management services across all stages of the product lifecycle, brings significant expertise to 1MED’s clinical offerings. Notably, LB Research has built a strong reputation          in oncology clinical trials, perfectly complementing 1MED’s capabilities. This strategic integration enhances 1MED’s clinical service portfolio for pharmaceutical and medical device studies, while solidifying its position in the European market.

For financial and tax matters, 1MED was advised by Mazars. The partners of LB Research were represented by BLF Studio Legale, with a team led by partner Andrea Corbelli and associate Davide Geraci, who managed the legal aspects of the transaction, including the partners’ reinvestment in the 1MED group.

Marco Polo Advisor assisted LB Research’s partners with financial matters and negotiations, ensuring a smooth and successful transaction.